Glufosfamide or analogs thereof have specific inhibitory effects on a cell having a specific gene mutation, in particular on a DNA repair-damaged cell. The cell or tissue has at least one gene mutation or more gene mutations in BRCA1, BRCA2, FANCD1, FANCD2, ATM, ATR, CHEK1, CHEK2, CTP, BARD1, BRIP1, PALB2, RAD51D, RAD51C, RAD52, RAD54, RAD55, RAD57, FAM175, NBN, Rad50, MER11, p53, NBS1, XRS2, XRCC2, XRCC3, ERCC1, ERCC2, ERCC3, ERCC4, XRCC1, Ku80, MHS6, MGMT, PARP and ERCC5. The analogs refer to esters obtained by means of esterification of one hydroxyl group or more hydroxyl groups in glufosfamide molecules with organic acids and inorganic oxy-acids; esters obtained by means of esterification of one hydroxyl group or more hydroxyl groups in glufosfamide molecules with amino acids; and salts obtained by means of a reaction of the glufosfamide molecule with acids. For this, pharmaceutical use of glufosfamide or analogs thereof for treating tumors and cancer diseases in cancer patients having the specific gene mutation(s) as mentioned above is provided.